Immunotherapy continues to be one of the most talked-about therapeutic approaches in oncology, but one niggling issue has been puzzling researchers even since the early clinical trials: Why do patients with seemingly similar cancers respond markedly differently to these drugs?
Researchers Uncover Major Clue In Predicting Response To Immunotherapy
